Skip to main content
. 2021 Jan 4;186(1):79–87. doi: 10.1007/s10549-020-06037-y

Fig. 4.

Fig. 4

PCLX-001 inhibits breast cancer growth in a murine MDA-MB-231 xenograft model. a Tumor volume in mice bearing MDA-MB-231 xenografts over 21 days of oral PCLX-001 administration daily at either 35 mg/kg or 50 mg/kg post tumor inoculation. b Average body weight of mice treated with daily 35 mg/kg or 50 mg/kg of PCLX-001 or vehicle alone for 21 days post tumor inoculation